Analysts Give AstraZeneca (LON:AZN) a £120 Price Target

set a £120 ($147.04) target price on AstraZeneca (LON:AZNGet Rating) in a research report report published on Monday, Borsen Zeitung reports.

Other equities analysts also recently issued reports about the company. Berenberg Bank reiterated a buy rating and set a £115 ($140.91) price objective on shares of AstraZeneca in a research report on Tuesday, July 26th. Credit Suisse Group set a £110 ($134.79) price objective on AstraZeneca in a report on Tuesday, June 7th. JPMorgan Chase & Co. set a £120 ($147.04) price target on AstraZeneca in a research report on Wednesday, July 13th. UBS Group set a £101 ($123.76) price objective on shares of AstraZeneca in a research report on Tuesday, June 14th. Finally, Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research report on Friday, July 22nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, AstraZeneca currently has a consensus rating of Buy and an average price target of £106.13 ($130.04).

AstraZeneca Stock Performance

LON:AZN opened at £106.62 ($130.65) on Monday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 90.06. The firm has a market capitalization of £165.21 billion and a price-to-earnings ratio of -181.33. The firm’s fifty day simple moving average is £106.02 and its 200 day simple moving average is GBX 9,951.88. AstraZeneca has a twelve month low of GBX 8,029 ($98.38) and a twelve month high of £112.90 ($138.34).

AstraZeneca Cuts Dividend

The firm also recently announced a dividend, which will be paid on Monday, September 12th. Shareholders of record on Thursday, August 11th will be given a GBX 76.40 ($0.94) dividend. This represents a yield of 0.7%. The ex-dividend date is Thursday, August 11th. AstraZeneca’s dividend payout ratio is -4.82%.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.